Key facts
- NexPlasmaGen’s last known valuation is $6.6M (Dec 2024).
- It has raised $960K; the latest was Later Stage VC ($360K) in Dec 2025.
- Notable investors include Government of Quebec, Kettlebeck Ventures, Aligo Innovation, Andy Ortaaslan, Campus des technologies de la santé — 25 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 25 names
- ·Watchlist + deal alerts for NexPlasmaGen
- ·The full record, as it builds
Funding rounds
No funding rounds for NexPlasmaGen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NexPlasmaGen
Developer of cold plasma delivery system designed to reduce cancer recurrence. The company's patented cold plasma device generates plasma species, producing cellular oxidative stress that kills cancer cells while sparing healthy tissue, enabling oncologist surgeons to reduce cancer recurrence after breast-conserving therapy and striving to reduce hospital direct costs while improving patient quality of life.
- Sector
- Healthcare
- HQ
- Montreal, Canada
- Founded
- 2008
- Employees
- 3
- Website
- nexplasmagen.com/
- Ownership
- Privately Held (backing)
NexPlasmaGen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NexPlasmaGen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NexPlasmaGen in its N-PORT filings yet. We sweep new filings monthly.